StockCall.com Provides Stock Research on Affymax Inc., Amgen Inc., PDL BioPharma Inc., Questcor Pharmaceuticals Inc., and BioCryst Pharmaceuticals Inc.
New York City, New York -- (June 07, 2013)
Last year, patents on several blockbuster drugs expired, leading to increasing competition from generic drug makers. The “patent cliff” is expected to result in further competition from generic drug makers. For the U.S. biotechnology sector, the patent cliff poses a significant challenge. The key for biotechnology companies will be to boost their product pipelines going forward. On Thursday, June 6, 2013, shares in biotechnology companies ended on a mixed note even as the broad market posted gains. The major movers in the sector includedAffymax Inc. (OTC: AFFY), Amgen Inc. (NASDAQ: AMGN), PDL BioPharma Inc. (NASDAQ: PDLI), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), and BioCryst Pharmaceuticals Inc. (NASDAQ: BCRX). StockCall has issued technical analysis and charting reports on AFFY, AMGN, PDLI, QCOR, and BCRX. Download these free reports now at
www.stockcall.com/todaysopinions
Affymax Inc.’s stock finished 7.50% lower at $1.11 with a total of 5.465 million shares traded during yesterday’s session. The stock’s usual trading volume stands at 9.469 million shares. In the past 52 weeks, the stock traded between $0.78 and $27.74. Affymax commands market capitalization of $41.61 million. Download the free research on AFFY today by registering at
www.StockCall.com/AFFY060713.pdf
Shares in Amgen Inc. showed robust gain on Thursday as it ended the session 3.05% higher at $97.49. A total of 4.67 million shares were traded during the session, while its average daily trading volume stands at 4.052 million. The stock oscillated between $94.15 and $97.53. Over the past five trading days, AMGN declined 7.95% while the markets wavered. Nonetheless, from the start of this year, shares of the company have increased by 14.37%. It is worth noting that Amgen’s shares have low volatility with beta of 0.41. The company commands market capitalization of $73.12 billion. Sign up and have access to our free report on AMGN at
www.StockCall.com/AMGN060713.pdf
PDL BioPharma Inc.’s stock ended 0.77% higher on Thursday at $7.88. A total of 2.31 million shares were traded. Despite the wider market swaying sideways during the past five trading sessions, the company’s shares declined 5.85%. Yet, the stock has added 11.14% so far this year. During yesterday’s session, the stock traded between $7.78 and $7.97 while its 52 weeks trading range stands at $6.18 and $8.48. PDL BioPharma commands market capitalization of $1.10 billion. Its stock is mildly volatile as implied by its beta of 0.33. Sign up and read the complimentary report on PDLI at
www.StockCall.com/PDLI060713.pdf
Questcor Pharmaceuticals Inc.’s stock hit an intra-day low of $33.00 to finish the day 2.61% higher at $34.18. A total of 700,790 shares were traded in comparison to its usual trading volume of 1.835 million shares. The stock is up 26.92% so far this year. In the past 52 weeks, QCOR traded between $17.25 and $58.91. Questcor’s shares show mild volatility as implied by its beta of 0.74. The stock is currently trading below its 20-day moving average price of $35.94 but above its 50-day moving average price of $32.59. The free report on QCOR can be downloaded by signing up now at
www.StockCall.com/QCOR060713.pdf
Shares in BioCryst Pharmaceuticals Inc. closed flat on Thursday, bucking the uptrend in the broader market. The stock hit an intraday high of $1.65, before closing at $1.65. So far this year, the share has gained more than 17%, slightly outperforming the S&P 500. The company’s stock currently trades below both their 20- and 50-day moving average price of $1.71 and $1.73 respectively. BioCryst saw turnover of 393,669 shares during yesterday’s trading session. Its beta of 2.55 implies high volatility. Free report on BCRX can be accessed by registering at
www.StockCall.com/BCRX060713.pdf
About StockCall.com
StockCall.com is a financial website where investors can have easy, precise and comprehensive research and opinions on stocks making the headlines. Sign up today to talk to our financial analyst at
www.stockcall.com
Contact Person:
William T. Knight
Email: info@stockcall.com
Contact Number: (646) 396-9857 (9:00 am EST – 01:30 pm EST)